Skip to main navigation Skip to search Skip to main content

In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation

  • Björn Erik Ole Jensen
  • , Elena Knops
  • , Leon Cords
  • , Nadine Lübke
  • , Maria Salgado
  • , Kathleen Busman-Sahay
  • , Jacob D. Estes
  • , Laura E.P. Huyveneers
  • , Federico Perdomo-Celis
  • , Melanie Wittner
  • , Cristina Gálvez
  • , Christiane Mummert
  • , Caroline Passaes
  • , Johanna M. Eberhard
  • , Carsten Münk
  • , Ilona Hauber
  • , Joachim Hauber
  • , Eva Heger
  • , Jozefien De Clercq
  • , Linos Vandekerckhove
  • Silke Bergmann, Gábor A. Dunay, Florian Klein, Dieter Häussinger, Johannes C. Fischer, Kathrin Nachtkamp, Joerg Timm, Rolf Kaiser, Thomas Harrer, Tom Luedde, Monique Nijhuis, Asier Sáez-Cirión, Julian Schulze zur Wiesch, Annemarie M.J. Wensing, Javier Martinez-Picado, Guido Kobbe
  • Heinrich Heine University Düsseldorf
  • University of Cologne
  • Partner Site Bonn-Cologne
  • University of Hamburg
  • IrsiCaixa AIDS Research Institute
  • Institute of Health Carlos III
  • Health Sciences Research Institute of the Germans Trias i Pujol Foundation
  • Oregon Health and Science University
  • Utrecht University
  • Institut Pasteur Paris
  • Partner Site Hamburg-Lübeck-Borstel-Riems
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Bavarian Nordic A/S
  • Helmholtz Institute for One Health
  • Leibniz Institute of Virology
  • Ghent University
  • University of the Witwatersrand
  • The University of Vic - Central University of Catalonia
  • ICREA

Research output: Contribution to journalArticlepeer-review

133 Scopus citations

Abstract

Despite scientific evidence originating from two patients published to date that CCR5Δ32/Δ32 hematopoietic stem cell transplantation (HSCT) can cure human immunodeficiency virus type 1 (HIV-1), the knowledge of immunological and virological correlates of cure is limited. Here we characterize a case of long-term HIV-1 remission of a 53-year-old male who was carefully monitored for more than 9 years after allogeneic CCR5Δ32/Δ32 HSCT performed for acute myeloid leukemia. Despite sporadic traces of HIV-1 DNA detected by droplet digital PCR and in situ hybridization assays in peripheral T cell subsets and tissue-derived samples, repeated ex vivo quantitative and in vivo outgrowth assays in humanized mice did not reveal replication-competent virus. Low levels of immune activation and waning HIV-1-specific humoral and cellular immune responses indicated a lack of ongoing antigen production. Four years after analytical treatment interruption, the absence of a viral rebound and the lack of immunological correlates of HIV-1 antigen persistence are strong evidence for HIV-1 cure after CCR5Δ32/Δ32 HSCT.

Original languageEnglish
Pages (from-to)583-587
Number of pages5
JournalNature Medicine
Volume29
Issue number3
DOIs
StatePublished - Mar 2023
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this